309 related articles for article (PubMed ID: 23333709)
21. New method for the effective production of ultrafine drug nanocrystals.
Möschwitzer J; Müller RH
J Nanosci Nanotechnol; 2006; 6(9-10):3145-53. PubMed ID: 17048530
[TBL] [Abstract][Full Text] [Related]
22. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods.
Peltonen L; Hirvonen J
J Pharm Pharmacol; 2010 Nov; 62(11):1569-79. PubMed ID: 21039542
[TBL] [Abstract][Full Text] [Related]
23. Recent advancements in mechanical reduction methods: particulate systems.
Leleux J; Williams RO
Drug Dev Ind Pharm; 2014 Mar; 40(3):289-300. PubMed ID: 23988193
[TBL] [Abstract][Full Text] [Related]
24. Progress in the study of drug nanocrystals.
Shi J; Guo F; Zheng A; Zhang X; Sun J
Pharmazie; 2015 Dec; 70(12):757-64. PubMed ID: 26817271
[TBL] [Abstract][Full Text] [Related]
25. Supercritical fluid technology: a promising approach in pharmaceutical research.
Girotra P; Singh SK; Nagpal K
Pharm Dev Technol; 2013 Feb; 18(1):22-38. PubMed ID: 23036159
[TBL] [Abstract][Full Text] [Related]
26. Particle design of poorly water-soluble drug substances using supercritical fluid technologies.
Yasuji T; Takeuchi H; Kawashima Y
Adv Drug Deliv Rev; 2008 Feb; 60(3):388-98. PubMed ID: 18068261
[TBL] [Abstract][Full Text] [Related]
27. A continuous and highly effective static mixing process for antisolvent precipitation of nanoparticles of poorly water-soluble drugs.
Dong Y; Ng WK; Hu J; Shen S; Tan RB
Int J Pharm; 2010 Feb; 386(1-2):256-61. PubMed ID: 19922777
[TBL] [Abstract][Full Text] [Related]
28. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation.
Keck CM; Müller RH
Eur J Pharm Biopharm; 2006 Jan; 62(1):3-16. PubMed ID: 16129588
[TBL] [Abstract][Full Text] [Related]
29. Long-term stability of quercetin nanocrystals prepared by different methods.
Kakran M; Shegokar R; Sahoo NG; Gohla S; Li L; Müller RH
J Pharm Pharmacol; 2012 Oct; 64(10):1394-402. PubMed ID: 22943170
[TBL] [Abstract][Full Text] [Related]
30. Drug nanoparticles: formulating poorly water-soluble compounds.
Merisko-Liversidge EM; Liversidge GG
Toxicol Pathol; 2008 Jan; 36(1):43-8. PubMed ID: 18337220
[TBL] [Abstract][Full Text] [Related]
31. Effect of drug physico-chemical properties on the efficiency of top-down process and characterization of nanosuspension.
Liu T; Müller RH; Möschwitzer JP
Expert Opin Drug Deliv; 2015; 12(11):1741-54. PubMed ID: 26098043
[TBL] [Abstract][Full Text] [Related]
32. Nanoparticles: A personal experience for formulating poorly water soluble drugs.
Cooper ER
J Control Release; 2010 Feb; 141(3):300-2. PubMed ID: 19822177
[TBL] [Abstract][Full Text] [Related]
33. Towards sustainability: new approaches to nano-drug preparation.
Cheow WS; Xu R; Hadinoto K
Curr Pharm Des; 2013; 19(35):6229-45. PubMed ID: 23469999
[TBL] [Abstract][Full Text] [Related]
34. Application of drug nanocrystal technologies on oral drug delivery of poorly soluble drugs.
Gao L; Liu G; Ma J; Wang X; Zhou L; Li X; Wang F
Pharm Res; 2013 Feb; 30(2):307-24. PubMed ID: 23073665
[TBL] [Abstract][Full Text] [Related]
35. Development of an oral rutin nanocrystal formulation.
Mauludin R; Müller RH; Keck CM
Int J Pharm; 2009 Mar; 370(1-2):202-9. PubMed ID: 19114097
[TBL] [Abstract][Full Text] [Related]
36. Combinative Particle Size Reduction Technologies for the Production of Drug Nanocrystals.
Salazar J; Müller RH; Möschwitzer JP
J Pharm (Cairo); 2014; 2014():265754. PubMed ID: 26556191
[TBL] [Abstract][Full Text] [Related]
37. Fabrication of quercetin nanocrystals: comparison of different methods.
Kakran M; Shegokar R; Sahoo NG; Shaal LA; Li L; Müller RH
Eur J Pharm Biopharm; 2012 Jan; 80(1):113-21. PubMed ID: 21896330
[TBL] [Abstract][Full Text] [Related]
38. A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability.
Quan P; Shi K; Piao H; Piao H; Liang N; Xia D; Cui F
Int J Pharm; 2012 Jul; 430(1-2):366-71. PubMed ID: 22531846
[TBL] [Abstract][Full Text] [Related]
39. Process optimization of a novel production method for nanosuspensions using design of experiments (DoE).
Salazar J; Heinzerling O; Müller RH; Möschwitzer JP
Int J Pharm; 2011 Nov; 420(2):395-403. PubMed ID: 21925582
[TBL] [Abstract][Full Text] [Related]
40. Comparison of different methods for preparation of a stable riccardin D formulation via nano-technology.
Liu G; Zhang D; Jiao Y; Zheng D; Liu Y; Duan C; Jia L; Zhang Q; Lou H
Int J Pharm; 2012 Jan; 422(1-2):516-22. PubMed ID: 22119965
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
